Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9403704 | 0.93 | ALDH1A1 (0.52) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL3746012 | 0.92 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL7345504 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL4027194 | 0.84 | KMT2A (0.45) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL11739098 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL27615767 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL14514418 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL7782945 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL7782947 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL30461727 | 0.80 | SLC15A1 (0.49) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479838-B2 | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220220102-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-07-14 | — | — | US | disclosed |
| EP-3953350-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | The United States of America, as Represented by The Department of Health and Human Services (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20100286386-A1 | Combinatorial production of nucleotide and nucleoside (XiTP) analogues | INSTITUT PASTEUR | 2010-11-11 | — | — | US | disclosed |
| US-7319148-B2 | Combinatorial production of nucleotide and nucleoside (XiTP) analogues | INSTITUT PASTEUR (FR) | 2008-01-15 | — | — | US | disclosed |
| EP-1780214-A2 | Combinatorial production of nucleotide and nucleoside analogues (XiTP) | INSTITUT PASTEUR (FR) | 2007-05-02 | — | — | EP | disclosed |
| EP-1290006-B1 | Combinatorial production of nucleotide and nucleoside (XITP) analogues | PASTEUR INSTITUT (FR) | 2007-02-21 | — | — | EP | disclosed |
| EP-1140909-B1 | NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORP (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040023240-A1 | Combinatorial production of nucleotide and nucleoside(xitp)analogues | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-02-05 | — | — | US | disclosed |
| EP-1290006-A1 | COMBINATORIAL PRODUCTION OF NUCLEOTIDE AND NUCLEOSIDE (XITP)ANALOGUES | INSTITUT PASTEUR (FR) | 2003-03-12 | — | — | EP | disclosed |
| US-6432959-B1 | ANTITUMOR AGENTS | SCHERING CORPORATION | 2002-08-13 | — | — | US | disclosed |
| WO-2001096354-A1 | COMBINATORIAL PRODUCTION OF NUCLEOTIDE AND NUCLEOSIDE (XITP)ANALOGUES | INSTITUT PASTEUR (FR) | 2001-12-20 | — | — | WO | disclosed |
| EP-1140909-A1 | NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039119-A1 | NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220102-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | DRD3, ADRB3, VDR | ALDH1A1 2173/4885MAPK1 3752/4885L3MBTL1 2037/4885 |
| US-20040023240-A1 | Combinatorial production of nucleotide and nucleoside(xitp)analogues | TYMP, PNP, DPYD | ALDH1A1 1635/4885MAPK1 517/4885L3MBTL1 2891/4885 |
| US-12479838-B2 | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof | DRD3, ADRB3, VDR | ALDH1A1 2173/4885MAPK1 3752/4885L3MBTL1 2037/4885 |
| US-20100286386-A1 | Combinatorial production of nucleotide and nucleoside (XiTP) analogues | TYMP, PNP, DPYD | ALDH1A1 2422/4885MAPK1 998/4885L3MBTL1 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.